Future Medications | Early Weight Loss Pipeline

The Basics

Where Phase 1 fits in the journey

Most drugs in Phase 1 never reach patients. But the ones that do can change medicine. Getting from Phase 1 to FDA approval typically takes 7 to 10 years.

You Are Here

🔬

Phase 1

Small groups. Is it safe?

Next Step

⚗️

Phase 2

Does it actually work?

Almost There

🚀

Phase 3

Thousands of people. Confirms results.

Finish Line

✅

FDA Approved

Available by prescription.

What's Being Explored

New ideas and a few real names

The next generation isn't just "more powerful GLP-1s." Some of what's in early trials represents genuinely different approaches to obesity treatment.

🦠

Phase 1b

BL-001 (Bloom Science)

Bloom Science · Gut microbiome approach

A completely different concept: an oral live biotherapeutic (a specially designed bacteria) that's meant to replicate the metabolic effects of a ketogenic diet without requiring you to actually change your diet. Phase 1 showed statistically significant weight loss. Phase 1b started in 2025 with 48 participants. Phase 2 planned for 2026. If it works, it's a whole new category.

No hormones, no GLP-1. A gut biology approach.

💊

Early Phase

Oral Triple Agonist Programs

Novo Nordisk, Hanmi, Lilly, Pfizer · GLP-1 + GIP + Glucagon in a pill

Retatrutide hits three hormones at once and showed 24% weight loss as an injection. Multiple companies are now racing to put the same triple mechanism into a daily pill. None have major Phase 2 data yet, but if any succeed it would be a significant leap: the highest weight loss numbers seen so far, without an injection.

The combination that doesn't exist yet. But everyone's trying.

⏳

Early Phase

Ultra Long Acting Formulations

Multiple companies · Monthly to quarterly dosing

MariTide already broke the weekly injection mold with once-monthly dosing. The next frontier is quarterly injections or even yearly implants. Long acting formulations are being designed because adherence is the hardest part of any long term treatment. Zealand Pharma, Novo Nordisk, and others are actively working on extended release formats that could make obesity treatment feel closer to a vaccine schedule than a daily routine.

One injection every 3 to 12 months. Being actively researched.

⚠️ Early stage means high risk of failure. Most won't reach patients. We reference only programs with published or publicly announced Phase 1+ data.

The Bigger Picture

Where we're headed

The drugs available today are already the best weight loss treatments ever developed. But the early pipeline makes clear we're probably in chapter two of a much longer story.

Now to 2026

Foundayo, Wegovy, and Zepbound available. CagriSema and Survodutide under FDA review.

2027 to 2028

Retatrutide, MariTide, CT-388, and Amycretin expected to complete Phase 3 and seek approval.

2029 to 2032

Early pipeline drugs reaching Phase 3. Muscle-preserving combos, oral triple agonists, and quarterly injectables could begin their final trials.

← See the full pipeline

This is Phase 1: Where New Drugs Are Born

Where Phase 1 fits in the journey

New ideas and a few real names

Where we're headed

Get notified when early drugs advance to Phase 2